Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
Status:
Completed
Trial end date:
2016-06-13
Target enrollment:
Participant gender:
Summary
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose
until 0.1 mg/Kg/d or less after 6 months of treatment. In this study, we hypothesized that
adding 3 months of tocilizumab to prednisone could increase the percentage from 40 to 70%.